Bristol-Myers Squibb (BMY) Granted EC Approval for Inrebic (fedratinib) for Adult Patients with Newly Diagnosed & Previously Treated Myelofibrosis
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
FDA Approves Bristol-Myers Squibb's (BMY) New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma
February 5, 2021 3:05 PM EST(Updated - February 5, 2021 3:06 PM EST)
Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma.
"Today's approval represents... More
Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Truist Securities
February 5, 2021 8:43 AM ESTTruist Securities raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $66.00 (from $65.00) while maintaining a Hold rating.... More
Bristol-Myers Squibb (BMY) Tops Q4 EPS by 5c, Offers FY Guidance
February 4, 2021 7:01 AM ESTBristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.46, $0.05 better than the analyst estimate of $1.41. Revenue for the quarter came in at $11.07 billion versus the consensus estimate of $10.73 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2021 EPS of $7.35-$7.55, versus the consensus... More
